AU2024283291A1 - Anti-synaptotagmin 2 antibody - Google Patents

Anti-synaptotagmin 2 antibody

Info

Publication number
AU2024283291A1
AU2024283291A1 AU2024283291A AU2024283291A AU2024283291A1 AU 2024283291 A1 AU2024283291 A1 AU 2024283291A1 AU 2024283291 A AU2024283291 A AU 2024283291A AU 2024283291 A AU2024283291 A AU 2024283291A AU 2024283291 A1 AU2024283291 A1 AU 2024283291A1
Authority
AU
Australia
Prior art keywords
antibody
present
motor neuron
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024283291A
Other languages
English (en)
Inventor
Norihiro YUMOTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiksak Bioengineering Inc
Original Assignee
Jiksak Bioengineering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiksak Bioengineering Inc filed Critical Jiksak Bioengineering Inc
Publication of AU2024283291A1 publication Critical patent/AU2024283291A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
AU2024283291A 2023-05-31 2024-05-30 Anti-synaptotagmin 2 antibody Pending AU2024283291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023090263 2023-05-31
JP2023-090263 2023-05-31
PCT/JP2024/019803 WO2024248063A1 (ja) 2023-05-31 2024-05-30 抗シナプトタグミン2抗体

Publications (1)

Publication Number Publication Date
AU2024283291A1 true AU2024283291A1 (en) 2026-01-08

Family

ID=93658011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024283291A Pending AU2024283291A1 (en) 2023-05-31 2024-05-30 Anti-synaptotagmin 2 antibody

Country Status (4)

Country Link
EP (1) EP4722242A1 (https=)
JP (1) JPWO2024248063A1 (https=)
AU (1) AU2024283291A1 (https=)
WO (1) WO2024248063A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
JP2008143867A (ja) 2006-12-12 2008-06-26 Institute Of Physical & Chemical Research シナプス形成促進剤
JP2012092048A (ja) 2010-10-27 2012-05-17 Keio Gijuku 軽度認知障害の治療用医薬剤、初期認知症の治療用医薬剤、神経細胞の樹状突起形成促進剤、神経細胞のシナプス形成促進剤、検定方法およびスクリーニング方法
CN103627676A (zh) * 2013-05-10 2014-03-12 深圳大学 多头绒泡菌14-3-3蛋白单克隆抗体及其制备方法
JP7323874B2 (ja) 2019-03-27 2023-08-09 国立大学法人東北大学 神経軸索分岐異常の改善剤
JP7849713B2 (ja) 2019-07-05 2026-04-22 株式会社Jiksak Bioengineering 神経細胞のシナプス形成誘導方法および該方法に用いるマイクロビーズ
JP2022053535A (ja) 2020-09-24 2022-04-05 株式会社Jiksak Bioengineering シナプス形成を促進するための組成物
US20220251241A1 (en) * 2021-02-08 2022-08-11 Ngm Biopharmaceuticals, Inc. Htra1-binding agents and methods of use thereof
JP2023028848A (ja) 2021-08-20 2023-03-03 株式会社Jiksak Bioengineering シナプス形成促進剤
JP7851719B2 (ja) 2021-12-17 2026-04-27 シャープ株式会社 表示装置、および、テレビジョン受像機
WO2023210585A1 (ja) 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤

Also Published As

Publication number Publication date
WO2024248063A1 (ja) 2024-12-05
JPWO2024248063A1 (https=) 2024-12-05
EP4722242A1 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
US20250277028A1 (en) Targeting agent
CN104781278B (zh) 针对tau的抗体
CN116966293A (zh) 脑信号蛋白-4d结合分子治疗神经变性疾病的用途
Jiang et al. Single-domain antibody-based protein degrader for synucleinopathies
González et al. Frizzled 1 and Wnt1 as new potential therapeutic targets in the traumatically injured spinal cord
AU2024283291A1 (en) Anti-synaptotagmin 2 antibody
AU2024281601A1 (en) Anti-synaptotagmin 2 antibody
WO2025084394A1 (ja) 抗シナプトタグミン2抗体
WO2025084396A1 (ja) 抗シナプトタグミン2抗体
WO2025084393A1 (ja) 抗シナプトタグミン2抗体
WO2025084397A1 (ja) 抗シナプトタグミン2抗体
WO2025084395A1 (ja) 抗シナプトタグミン2抗体
WO2025089342A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089341A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089344A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089343A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089345A1 (ja) 抗シナプトジャイリン3抗体
WO2025089346A1 (ja) 抗シナプトフィジン抗体
WO2025089349A1 (ja) 抗シナプトフィジン抗体
WO2025089347A1 (ja) 抗シナプトフィジン抗体
WO2025089348A1 (ja) 抗シナプトフィジン抗体
WO2023220639A2 (en) Methods and compositions for improved memory in the aging
CA3257052A1 (en) Targeting agent
US20250346635A1 (en) Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
Huang et al. Isolation, culture, and characterization of primary endothelial cells and pericytes from mouse sciatic nerve